View in EDS HTML Full Text PDF Full Text

IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.

Saved in:
Bibliographic Details
Title: IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.
Authors: Hack SP; Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA., Verret W; Genentech, South San Francisco, CA, USA., Mulla S; Hoffmann-La Roche Limited, Mississauga, ON, Canada., Liu B; Genentech, South San Francisco, CA, USA., Wang Y; Genentech, South San Francisco, CA, USA., Macarulla T; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain., Ren Z; Zhongshan Hospital, Fudan University, Shanghai, China., El-Khoueiry AB; USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA., Zhu AX; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Source: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2021 Jul 31; Vol. 13, pp. 17588359211036544. Date of Electronic Publication: 2021 Jul 31 (Print Publication: 2021).
Publication Type: Journal Article
Journal Info: Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34377158
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Hack+SP%22">Hack SP</searchLink>; Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA.<br /><searchLink fieldCode="AU" term="%22Verret+W%22">Verret W</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Mulla+S%22">Mulla S</searchLink>; Hoffmann-La Roche Limited, Mississauga, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Liu+B%22">Liu B</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wang+Y%22">Wang Y</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Macarulla+T%22">Macarulla T</searchLink>; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Ren+Z%22">Ren Z</searchLink>; Zhongshan Hospital, Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22El-Khoueiry+AB%22">El-Khoueiry AB</searchLink>; USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Zhu+AX%22">Zhu AX</searchLink>; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101510808%22">Therapeutic advances in medical oncology</searchLink> [Ther Adv Med Oncol] 2021 Jul 31; Vol. 13, pp. 17588359211036544. <i>Date of Electronic Publication: </i>2021 Jul 31 (<i>Print Publication: </i>2021).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Sage%22">Sage </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101510808 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1758-8340 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217588340%22">17588340 </searchLink><i>NLM ISO Abbreviation: </i>Ther Adv Med Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34377158
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1177/17588359211036544
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 17588359211036544
    Titles:
      – TitleFull: IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hack SP
      – PersonEntity:
          Name:
            NameFull: Verret W
      – PersonEntity:
          Name:
            NameFull: Mulla S
      – PersonEntity:
          Name:
            NameFull: Liu B
      – PersonEntity:
          Name:
            NameFull: Wang Y
      – PersonEntity:
          Name:
            NameFull: Macarulla T
      – PersonEntity:
          Name:
            NameFull: Ren Z
      – PersonEntity:
          Name:
            NameFull: El-Khoueiry AB
      – PersonEntity:
          Name:
            NameFull: Zhu AX
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 31
              M: 07
              Text: 2021 Jul 31
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-print
              Value: 1758-8340
          Numbering:
            – Type: volume
              Value: 13
          Titles:
            – TitleFull: Therapeutic advances in medical oncology
              Type: main
ResultId 1